CymaBay Therapeutics's competitors

CymaBay Therapeutics's competitors include Collegium Pharmaceutical, Esperion Therapeutics, Cara Therapeutics and RXi Pharmaceuticals
Add company...
CymaBay Therapeutics
CymaBay Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies to treat metabolic diseases with high unmet medical need or serious rare and orphan diseases.
Collegium Pharmaceutical
Collegium Pharmaceutical is a specialty pharmaceutical company focused on the development of products for the treatment of chronic pain.
Esperion Therapeutics
Esperion Therapeutics discovers and develops pharmaceutical products for the treatment of cardiovascular and metabolic diseases.
Cara Therapeutics
Cara Therapeutics is a biotechnology company focused on developing therapeutics to treat diseases associated with pain and inflammation.
RXi Pharmaceuticals
RXi Pharmaceuticals develops therapeutics based on ribonucleic acid interference.
Founding Date
Founding Date
1991
Founding Date
2002
Founding Date
2008
Founding Date
2004
Founding Date
2011
Type
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Newark, US HQ
Locations
Canton, US HQ
Locations
Ann Arbor, US HQ
Locations
Stamford, US HQ
Locations
Marlborough, US HQ
Employees
Employees
21
Employees
234
Employees
44
Employees
34
Employees
15
Valuation ($)
Valuation ($)
453.4 m
Valuation ($)
754.2 m
Valuation ($)
1.8 b
Valuation ($)
394.1 m
Valuation ($)
6.3 m
Twitter followers
Twitter followers
N/A
Twitter followers
N/A
Twitter followers
895
Twitter followers
N/A
Twitter followers
216

Financial

Net income
Net income
($27.6m) (FY, 2017)
Net income
($74.9m) (FY, 2017)
Net income
($75m) (FY, 2016)
Net income
N/A
Net income
($12.5m) (FY, 2017)
For sources of this data, please see the company profileDownload Excel

View company profiles